Sumitomo Chemical Company (4005) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
6 Aug, 2026Executive summary
Core operating income rose to ¥62.3 billion in Q1 FY2026, up from ¥27.7 billion year-on-year, marking the second-best Q1 on record after FY2022.
Net income attributable to owners was ¥40.8 billion, a sharp turnaround from a ¥4.5 billion loss in Q1 FY2025, driven by improved profitability across key segments.
All business segments reported increased sales revenue, with significant contributions from Essential & Green Materials, Agro & Life Solutions, and ICT & Mobility Solutions.
Essential & Green Materials drove core operating income, aided by improved profit margins and temporary inventory valuation gains.
ICT & Mobility Solutions benefited from higher semiconductor material shipments despite weaker display-related sales.
Financial highlights
Consolidated sales revenue reached ¥578.2 billion, up 9.9% or ¥52.1 billion year-on-year.
Operating income was ¥61.0 billion, up ¥35.6 billion or 139.8% year-on-year.
Gross profit increased to ¥194.2 billion from ¥163.7 billion year-on-year.
Free cash flow was negative ¥44.3 billion, a deterioration of ¥22.3 billion year-on-year.
ROE improved to 3.9% from -0.5% year-on-year.
Outlook and guidance
First-half FY2026 forecasts: core operating income of ¥125.0 billion and net income of ¥70.0 billion, both expected to double year-on-year.
Sales revenue for the first half projected at ¥1,170.0 billion, up ¥74.6 billion year-on-year.
Full-year FY2026 sales revenue forecast is ¥2,360.0 billion, with core operating income at ¥215.0 billion and net income at ¥70.0 billion.
No revision to full-year forecast due to ongoing geopolitical uncertainties; reassessment planned at first-half results.
Interim and annual dividend guidance maintained at ¥8.00 and ¥16.00 per share, respectively.
Latest events from Sumitomo Chemical Company
- Core operating income and net income rose sharply, with FY2026 set for further growth.4005
Q4 2026 - Profits soared year-over-year, prompting upward revisions to forecasts and dividends.4005
Q3 2026 - Profitability rebounded sharply, driven by pharma gains, asset sales, and improved margins.4005
Q2 2026 - Growth strategy leverages tech strengths, reforms, and portfolio upgrades for resilience and efficiency.4005
Status Update - Core operating income rose sharply despite lower sales and FX losses; outlook is positive.4005
Q1 2026 - V-shaped profit recovery and portfolio restructuring drive improved FY2024 outlook.4005
Q2 2025 - Targets JPY 200B core income by 2027 and JPY 350B by 2035, led by Agro and ICT growth.4005
Status Update - FY2024 saw a sharp profit rebound and improved cash flow, with higher dividends ahead.4005
Q4 2025 - Q3 FY2024 delivered a strong profit rebound and segment growth, with guidance maintained.4005
Q3 2025